ProSomnus Inc News - OSA

Professional-Grade Tools, for Individual Investors.

Premium

ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in...

ProSomnus® Appoints Brian Dow as Chief Financial Officer

PLEASANTON, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

Amended Statement of Ownership (sc 13g/a)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Stocks to Watch: Meta, Tenax, Align Technology, ProSomnus

Sabela Ojea Meta Platforms Inc. on Wednesday beat revenue expectations for its latest quarter and reported improving conditions that point to...

ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance

SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in...

ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference

SAN FRANCISCO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in...

ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)

First prospective crossover study comparing the effectiveness of precision oral appliance therapy as front-line...

ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea

SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in...

ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device

SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in...

Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy

Treatment with Precision Oral Appliance Therapy Demonstrated Significant Improvements in Apnea-Hypopnea Events...

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices

Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq...

OSAPQ: BK PLAN effective. All shares and warrants cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

👍️0

Renee 8 months ago

Effective May 9,2024 OSAP will change to OSAPQ, bankruptcy.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

👍️0

Renee 9 months ago

OSA changed to OSAP. Delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

👍️0

TrendTrade2016 1 year ago

OSA here comes 1.20

👍️0

TrendTrade2016 1 year ago

OSA wants 1.20

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ProSomnus Inc (OSA)

Professional-Grade Tools, for Individual Investors.

OSA News

ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

ProSomnus® Appoints Brian Dow as Chief Financial Officer

Amended Statement of Ownership (sc 13g/a)

Stocks to Watch: Meta, Tenax, Align Technology, ProSomnus

ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance

ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference

ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)

ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea

ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device

Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices

Cancel - OneSaturday Plc

Further re Delisting

Directorate Change

OSA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ProSomnus Inc (OSA) News

ProSomnus Inc (OSA)

Professional-Grade Tools, for Individual Investors.

OSA News

ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

ProSomnus® Appoints Brian Dow as Chief Financial Officer

Amended Statement of Ownership (sc 13g/a)

Stocks to Watch: Meta, Tenax, Align Technology, ProSomnus

ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance

ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference

ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)

ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea

ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device

Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices

Cancel - OneSaturday Plc

Further re Delisting

Directorate Change

OSA Discussion

Your Recent History

Go Ad-Free